Secondary analysis of CONFIDENCE in participants with CKD and type 2 diabetes: older age (-10.2% per decade) and female sex (18.6% more than men) predicted greater UACR reduction at day 180 with finerenone, empagliflozin or both; neither modified the combination's effect.
Secondary analysis
Agarwal et al. Sexual dimorphism and age effects in CKD and type 2 diabetes in the CONFIDENCE trial